Glioblastoma (GBM) is an aggressive brain tumor characterized by marked intra- and inter-tumoral heterogeneity and inevitable recurrence. Although extracranial metastasis is rare, circulating tumor ...

Guildford, Surrey, UK - September 21, 2015 - Research conducted at Barts Cancer Institute, Queen Mary University, London, published today in PLOS ONE demonstrates that the Parsortix Cell Separation ...

ANGLE plc's Parsortix, which was granted a European patent in March 2016, harvests circulating cancer cells from blood for further medical analysis. Its use is an essential step in research under the ...

New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer Understanding the genetic diversity of CTC clusters is of clinical ...

GUILDFORD, England--(BUSINESS WIRE)--ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announced the presentation of independent study data by Western University on ...

FDA and EU filings for blood-based circulating tumor cell diagnostic are projected for 2013. Cancer diagnostics firm Parsortix signed a two-year agreement with the Cancer Research UK-funded Paterson ...

ANGLE plc, the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute’s ongoing work with ANGLE’s Parsortix system have provided evidence in support of the use ...

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased ...

Angle plc, a world leading liquid biopsy company, announced positive results from a pilot study to investigate the potential of Angle’s Parsortix system to harvest fetal cells from the peripheral ...

GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research ...